Registration procedures for generic drugs in the EU Posted 05/08/2011

In the EU there are several different routes to marketing authorisation for generic drugs. Centralised Procedure Marketing authorisation is issued by the EMA and is valid for the entire EU/European Economic Area. This procedure is optional for generics:
Mutual Recognition Procedure/Decentralised Procedure This is the only route available for generic drugs if the reference product is authorised nationally. The CMDh (Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human) is responsible for the examination of any question relating to marketing authorisation of a medicinal product in two or more Member States in accordance with the Mutual Recognition Procedure (MRP) or the Decentralised Procedure (DCP). Generic medicines account for the majority of marketing authorisation submissions in the DCP and MRP. Generic applications in 2010 accounted for 64.3% of MRPs and a staggering 84.7% of DCPs. National procedure This is only applicable if the generic submission is carried out in only one country. Marketing authorisation will then only be applicable to that one country. This can in some cases be done prior to a MRP. Related articles A sustainable generics industry in the EU The role of generic drugs in the EU Generic drugs – registration, quality, value and sustainability
Source: CMDh annual report 2010, EGA, EU Official Journal
Comments (0)
Generics News Research General
- Adherence improves long-term prognosis and medi...Generics/Research | Posted 19/02/2021
- Anti-competitive strategic patenting by pharmac...Generics/Research | Posted 12/02/2021
- Biocon and Lupin launch generic tacrolimus caps...Generics/News | Posted 05/02/2021
- New generics company to offer low-cost versions...Generics/General | Posted 29/01/2021
Biosimilars News Research General
- Improving stakeholder understanding about biosi...Biosimilars/Research | Posted 19/02/2021
- Canada approves infliximab biosimilar Remsima SCBiosimilars/News | Posted 19/02/2021
- Innovent starts phase II trial for ipilimumab c...Biosimilars/News | Posted 19/02/2021
- EMA recommends approval of adalimumab biosimila...Biosimilars/News | Posted 12/02/2021